Propanc Biopharma plans Phase 1b PRP trial in up to 50 advanced cancer patients

• Propanc Biopharma is advancing preparations for a Phase 1b first-in-human trial of PRP in up to 50 advanced cancer patients.
• The proposed multicenter study will evaluate dose escalation and expansion in advanced or metastatic solid tumors; pancreatic cancer is the lead indication.
• First-site initiation is targeted for February 2027, followed by patient screening, subject to clinical, regulatory, ethics and operational requirements.
• Ethics submission is targeted for November 2026, with regulatory activities scheduled for January 2027.
• The announcement covers preparations for future clinical evaluation, rather than trial results; PRP has U.S. FDA orphan drug designation for pancreatic cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280830PRIMZONEFULLFEED9854954) on October 28, 2026, and is solely responsible for the information contained therein.